

October 24, 2023

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Kae Miyata
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554

Notice of the Settlement of Patent Infringement Litigation in the U.S.

[Chugai Pharmaceutical Co., Ltd.](#) (Headquarters: Tokyo, Japan, hereafter Chugai) announced that Chugai, Roche and Genentech (collectively, the Companies) have settled globally with Biogen MA Inc. (hereafter, Biogen) and Bio-Thera Solutions, Ltd. (hereafter, Bio-Thera) on October 23 (local time) in relation to Biogen and Bio-Thera's biosimilar referencing Actemra[®] (generic name: tocilizumab) subject to patent infringement lawsuit in the U.S.. Subsequently, the Companies, Biogen and Bio-Thera will take steps to withdraw the following lawsuit.

<Patent infringement lawsuit to be withdrawn>

Lawsuit filed at the United States District Court for the District of Massachusetts

Dates of Complaint: July 13, 2023 (local time)

Plaintiff: Chugai, Roche and Genentech

Defendant: Biogen MA Inc. and Bio-Thera Solutions, Ltd.

Patents in suit: Patents related to methods of using tocilizumab in intravenous form, and methods of manufacturing tocilizumab.

The impact on the consolidated financial results for the fiscal year ending December 2023 of Chugai is expected to be negligible.

###